Use of Injection Solcoseryl for the treatment of oligohydramnios
Khurshid Shabbir Raja, Huma Tasleem.
To assess the efficacy of drug hemodialysate (solcoseryl) on liquor volume in intrauterine growth restricted (IUGR) babies and their outcome in view of APGAR score and their health status.
Patients and Methods
In this study, a total of 70 patients with IUGR were included and it was carried out at Shifa International Hospital and Shifa Foundation Community Health Clinic Islamabad from January 2006 to December 2008. The patients were divided in two groups with 35 in each group. In group one, no infusion of solcoseryl was given, only left lateral position and plenty of fluids were advised (Conventional therapy). In group two, 10 mg of solcoseryl was given in 500 ml of normal saline at the rate of 125 ml/hour per day after 28 weeks of gestation (Interventional therapy). If the patient was hypertensive, 500 ml of Dextrose water was used instead of normal saline. Minimum one dose and maximum 28 doses were used. Both groups were compared with level of amniotic fluid index before and after the treatment.
Out of 70 patients, frequency of IUGR in group one it was 6.83±2.24, (t = -3.28, 95% CI, -2.89 -.704),
Solcoseryl is the drug of choice in pregnant women with IUGR, especially after twenty eight week of gestation.
Solcoseryl, oligohyramnios, IUGR.
Warning: mysql_num_rows() expects parameter 1 to be resource, boolean given in /home/ejman/depo/functions_site.php on line 909
Indexed in WHO Index Medicus IMEMR, Emromedex, Pakmedinet, ExtraMED and Scopus
Approved by the Higher Education Commission of Pakistan and Pakistan Medical and Dental Council